November 28, 2020 10:47am

A scorecard of 34 earnings releases and 1 acquisition of 35 covered companies

The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status"

 


COMPANY 

SYMBOL NET INCOME Q3/20 LOSS Q3/20 LPS Q2/20 CASH RUNWAY

Chinook Therapeutics

formerly, Aduro

Biotech (ADRO)

KDNY   –$14.5 M –$0.90 $74.31 M 2022

Alnylam

Pharmaceuticals

ALNY   –$253.2 M –$2.18

$1.83 Billion

N/A
Applied Genetic Technologies AGTC  

–$15.4 M

–$0.60

$66.6 M 04/21 
Athersys, Inc. ATHX   –$22.5 M –$0.11

$61.7 M

Q4/21

Adverum

Biotechnologies

ADVM   –$27.8 M –$0.31

$454.5 M

mid-2022
AxoGen AXGN   –$1.5 M –$0.04 $106.7 M 2022

Bellicum

Pharmaceuticals

BLCM

 

–$900 K –$0.18 $54.6 M Q2/22

BioLife

Solutions

BLFS

 

–$1.1 M –$0.04

$109 M 

2024
Biostage BSTG   –$700 K –$0.07

$2 M

Q1/21
bluebird bio BLUE   -$194.7 M –$2.94 $1.44 B 2023 
Brainstorm Cell Therapeutics BCLI   –$4.49 M –$0.70

$28.8 M

2021

Caladrius

Biosciences.

CLBS   –$5.3 M –$0.29

$40.3 M

Q2/21

Cellectis SA CLLS

 

–$30 M –$0.71 $308 M 2022

CRISPR

Therapeutics

CRSP   –$92.4 M –$1.32 $1.4 B 2023

Editas

Medicine

EDIT

+7.8 M or

+$0.12

    $541.3 M 2023

Fate

Therapeutics

FATE   –$58.6 M –$0.68

$502 M

2022

Global Blood

Therapeutics

GBT   –$59.9 M –$0.97 $535.2 M 2024

Homology

Medicine

FIXX   –$28.2 M –$0.62 $178 M 2022

Intellia

Therapeutics

NTLA   –$27.8 M –$0.47 $407.9 M 2022

Precigen

formerly

Intrexon 

PGEN   –$29.5 M –$0.18 $113.1 M 2021

Ionis

Pharmaceuticals

IONS

 

 

–$14.5 M –$7.00 $2.35 B N/A
Mesoblast MESO  

–$X M

–$X

$X M 

 
MiMedx Group

MDXG

 

–$19.4 M

–$0.48

$109.6 M

Q2/2022

Pluristem

Therapeutics

PSTI   –$X M –$X

$59 M

2021

ReNeuron

Group

RENE.L          
Regenxbio RGNX   –$8.8 M –$0.24 $289.8 M mid-22

Sage

Therapeutics

SAGE   –$105.7 M –$2.03 $671 M 2022

Sangamo

Biosciences

SGMO   –$1.6 M –$0.01

$694.5 M

2022

Solid

Biosciences

SLDB  

–$21.2 M

–$0.44 $24.8 M 2H/21
StemlineTherapeutics STML

Acquired by

Menarini, an

Italian pharma

       
Ultragenyx RARE   -$68.8 M -$1.13 $7.65 M N/A 
uniQure N.V. QURE   –$53.8 M –$1.21 $279.5 M 2h/24
Verastem VSTM   –$1.31 M –$0.08

$205.7 M

2024
Vericel VCEL   –$3.6 M –$0.08 $85.5 M 2022

Voyager

Therapeutics

VYGR

+$85.6 M or

+2.27

    $200 M mid-2022